116 patents
Utility
Targeted gene insertion for improved immune cells therapy
16 Jan 24
The invention pertains to the field of adaptive cell immunotherapy.
Brian Busser, Philippe Duchateau, Alexandre Juillerat, Laurent Poirot, Julien Valton
Filed: 19 Oct 17
Utility
Use of Aminoquinoline Compounds for Higher Gene Integration
28 Dec 23
The invention provides aminoquinoline compounds as powerful enhancers of genetic recombination in living cells, especially to perform site-directed gene integration of exogenous DNA template by homologous recombination.
Alexandre JUILLERAT, Philippe DUCHATEAU, Ming YANG
Filed: 30 Nov 21
Utility
Method for generating T-cells compatible for allogenic transplantation
21 Nov 23
The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy.
Laurent Poirot, David Sourdive, Philippe Duchateau, Jean-Pierre Cabaniols
Filed: 21 Sep 18
Utility
Cells for Immunotherapy Engineered for Targeting Antigen Present Both on Immune Cells and Pathological Cells
9 Nov 23
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSI or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Philippe DUCHATEAU, Laurent POIROT
Filed: 22 May 23
Utility
Repeat variable diresidues for targeting nucleotides
10 Oct 23
The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids.
Philippe Duchateau, Alexandre Juillerat, Claudia Bertonati
Filed: 15 Mar 13
Utility
Sequence specific reagents targeting CCR5 in primary hematopoietic cells
26 Sep 23
The invention pertains to the field of cell therapy and HIV treatments.
Toni Cathomen, Tatjana Cornu, Philippe Duchateau, Claudio Mussolino, Marianna Romito, Agnes Gouble
Filed: 13 Apr 18
Utility
Sequential Gene Editing In Primary Immune Cells
14 Sep 23
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
Filed: 19 Apr 23
Utility
Dual Car-t Cells
7 Sep 23
The present invention concerns new engineered immune cells expressing two CARs directed against two different targets, polynucleotides for preparing said immune cells, pharmaceutical compositions comprising said immune cells, and the use of said immune cells in the treatment of cancers.
André CHOULIKA, Laurent POIROT, Beatriz ARANDA ORGILLES, Philippe DUCHATEAU
Filed: 30 Jul 21
Utility
Methods to Genetically Modify Cells for Delivery of Therapeutic Proteins
7 Sep 23
The present disclosure provides methods to genetically modify cells by insertion of an artificial exon (ArtEx) for delivery of therapeutic proteins in specific cell types and more particularly engineered cells for expression of a transgene into the brain of a patient.
Alexandre JUILLERAT, Philippe DUCHATEAU, Patrick HONG, Laurent POIROT, Brian BUSSER, Alex BOYNE
Filed: 6 May 21
Utility
T-cells Expressing Immune Cell Engagers In Allogenic Settings
10 Aug 23
The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.
Shipra DAS, Sumin JO, Alexandre JUILLERAT, Julien VALTON, Laurent POIROT, Philippe DUCHATEAU
Filed: 23 Jul 21
Utility
Method for determining potency of chimeric antigen receptor expressing immune cells
20 Jul 23
The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.
Xenia NAJ, Anne-Sophie Petit, Roman Galetto, Jean-Pierre Cabaniols
Filed: 2 Jul 21
Utility
Methods for Targeted Insertion of Exogenous Sequences In Cellular Genomes
6 Jul 23
The present disclosure provides methods for targeted insertion of an exogenous sequence at a genomic locus in a cell, wherein said insertion is induced by a sequence-specific endonuclease that has cleavage activity at said locus, at least 5 hours before the introduction into said cell of a DNA template comprising said exogenous sequence.
Ming YANG, Alexandre JUILLERAT, Philippe DUCHATEAU, Patrick HONG
Filed: 6 May 21
Utility
Universal chimeric antigen receptor T cells specific for CD22
4 Jul 23
The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy.
Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
Filed: 30 Mar 18
Utility
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
4 Jul 23
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Philippe Duchateau, Laurent Poirot
Filed: 27 Jul 20
Utility
Methods for Engineering Allogeneic and Highly Active T Cell for Immunotheraphy
29 Jun 23
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 17 Nov 22
Utility
Compact scaffold of Cas9 in the type II CRISPR system
27 Jun 23
The present invention is in the field of CRISPR-Cas system for genome targeting.
Philippe Duchateau, Claudia Bertonati
Filed: 28 May 14
Utility
Combination Comprising Allogeneic Immune Cells Deficient for an Antigen Present on Both T-cells and Pathological Cells and Therapeutic Antibody Against Said Antigen
25 May 23
The present invention relates to a therapeutic combination of immune cells, preferably allogeneic non-alloreactive TCR-KO immune T cells, wherein a gene coding an antigen marker X present on both T-cells and pathological cells is inactivated and a corresponding therapeutic antibody specific for said antigen marker X, method for preparing the same and use in immunotherapy.
Philippe DUCHATEAU
Filed: 30 Jan 19
Utility
TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY
4 May 23
The invention relates to the fields of immunotherapy, molecular biology and recombinant nucleic acid technology.
Philippe DUCHATEAU, Brian BUSSER, Alexandre JUILLERAT, Anne-Sophie GAUTRON, Laurent POIROT
Filed: 19 Oct 17
Utility
Canola with high oleic acid
11 Apr 23
Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein.
Wenzheng Zhang, Feng Zhang
Filed: 9 Jul 19
Utility
Sequential Gene Editing In Primary Immune Cells
23 Mar 23
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
Filed: 5 Aug 22